1
|
Ng ASL, Tan AH, Tan YJ, Lim JL, Lian MM, Dy Closas AM, Ahmad-Annuar A, Viswanathan S, Chia YK, Foo JN, Lim WK, Tan EK, Lim SY. Identification of Genetic Variants in Progressive Supranuclear Palsy in Southeast Asia. Mov Disord 2024. [PMID: 39149795 DOI: 10.1002/mds.29932] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2024] [Revised: 06/21/2024] [Accepted: 07/01/2024] [Indexed: 08/17/2024] Open
Abstract
BACKGROUND Progressive supranuclear palsy (PSP) is largely a sporadic disease with few reported familial cases. Genome-wide association studies (GWAS) in sporadic PSP in Caucasian populations have identified MAPT as the most commonly associated genetic risk locus with the strongest effect size. At present there are limited data on genetic factors associated with PSP in Asian populations. OBJECTIVES Our goal was to investigate the genetic factors associated with PSP in Southeast Asian PSP patients. METHODS Next-generation sequencing (whole-exome, whole-genome and targeted sequencing) was performed in two Asian cohorts, comprising 177 PSP patients. RESULTS We identified 17 pathogenic or likely pathogenic variants in 16 PSP patients (9%), eight of which were novel. The most common relevant genetic variants identified were in MAPT, GBA1, OPTN, SYNJ1, and SQSTM1. Other variants detected were in TBK1, PRNP, and ABCA7-genes that have been implicated in other neurodegenerative diseases. Eighteen patients had a positive family history, of whom two carried pathogenic MAPT variants, and one carried a likely pathogenic GBA1 variant. None of the patients had expanded repeats in C9orf72. Furthermore, we found 16 different variants of uncertain significance in 21 PSP patients in PSEN2, ABCA7, SMPD1, MAPT, ATP13A2, OPTN, SQSTM1, CYLD, and BSN. CONCLUSIONS The genetic findings in our PSP cohorts appear to be somewhat distinct from those in Western populations, and also suggest an overlap of the genetic architecture between PSP and other neurodegenerative diseases. Further functional studies and validation in independent Asian cohorts will be useful for improving our understanding of PSP genetics and guiding genetic screening strategies in these populations. © 2024 International Parkinson and Movement Disorder Society.
Collapse
Affiliation(s)
- Adeline Su Lyn Ng
- Department of Neurology, National Neuroscience Institute, Singapore, Singapore
- Neuroscience and Behavioural Disorders Programme, Duke-NUS Medical School, Singapore, Singapore
- Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore
| | - Ai Huey Tan
- Division of Neurology, Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
- Mah Pooi Soo and Tan Chin Nam Centre for Parkinson's and Related Disorders, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
| | - Yi Jayne Tan
- Department of Neurology, National Neuroscience Institute, Singapore, Singapore
| | - Jia Lun Lim
- Department of Biomedical Science, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
| | - Michelle Mulan Lian
- Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore
| | - Alfand Marl Dy Closas
- Division of Neurology, Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
- Mah Pooi Soo and Tan Chin Nam Centre for Parkinson's and Related Disorders, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
- Metro Davao Medical and Research Center, Davao Doctors Hospital, Davao City, Philippines
| | - Azlina Ahmad-Annuar
- Department of Biomedical Science, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
| | | | - Yuen Kang Chia
- Department of Neurology, Queen Elizabeth Hospital, Kota Kinabalu, Sabah, Malaysia
| | - Jia Nee Foo
- Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore
- Genome Institute of Singapore, Agency for Science, Technology and Research, Singapore
| | - Weng Khong Lim
- Genome Institute of Singapore, Agency for Science, Technology and Research, Singapore
- Singhealth Duke-NUS Institute of Precision Medicine, Singapore
- Cancer and Stem Cell Biology Program, Duke-NUS Medical School, Singapore
- SingHealth Duke-NUS Genomic Medicine Centre, Singapore
| | - Eng-King Tan
- Department of Neurology, National Neuroscience Institute, Singapore, Singapore
- Neuroscience and Behavioural Disorders Programme, Duke-NUS Medical School, Singapore, Singapore
- Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore
| | - Shen-Yang Lim
- Division of Neurology, Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
- Mah Pooi Soo and Tan Chin Nam Centre for Parkinson's and Related Disorders, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
| |
Collapse
|
2
|
Cóppola-Segovia V, Reggiori F. Molecular Insights into Aggrephagy: Their Cellular Functions in the Context of Neurodegenerative Diseases. J Mol Biol 2024; 436:168493. [PMID: 38360089 DOI: 10.1016/j.jmb.2024.168493] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2023] [Revised: 02/06/2024] [Accepted: 02/09/2024] [Indexed: 02/17/2024]
Abstract
Protein homeostasis or proteostasis is an equilibrium of biosynthetic production, folding and transport of proteins, and their timely and efficient degradation. Proteostasis is guaranteed by a network of protein quality control systems aimed at maintaining the proteome function and avoiding accumulation of potentially cytotoxic proteins. Terminal unfolded and dysfunctional proteins can be directly turned over by the ubiquitin-proteasome system (UPS) or first amassed into aggregates prior to degradation. Aggregates can also be disposed into lysosomes by a selective type of autophagy known as aggrephagy, which relies on a set of so-called selective autophagy receptors (SARs) and adaptor proteins. Failure in eliminating aggregates, also due to defects in aggrephagy, can have devastating effects as underscored by several neurodegenerative diseases or proteinopathies, which are characterized by the accumulation of aggregates mostly formed by a specific disease-associated, aggregate-prone protein depending on the clinical pathology. Despite its medical relevance, however, the process of aggrephagy is far from being understood. Here we review the findings that have helped in assigning a possible function to specific SARs and adaptor proteins in aggrephagy in the context of proteinopathies, and also highlight the interplay between aggrephagy and the pathogenesis of proteinopathies.
Collapse
Affiliation(s)
| | - Fulvio Reggiori
- Department of Biomedicine, Aarhus University, Ole Worms Allé 4, 8000 Aarhus C, Denmark; Aarhus Institute of Advanced Studies (AIAS), Aarhus University, Høegh-Guldbergs Gade 6B, 8000 Aarhus C, Denmark.
| |
Collapse
|
3
|
Zhu Y, Li M, Wang H, Yang F, Du R, Pang X, Bai J, Huang X. Mendelian Randomization Identifies Genetically Supported Drug Targets for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Mol Neurobiol 2024; 61:3809-3818. [PMID: 38019415 DOI: 10.1007/s12035-023-03817-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2023] [Accepted: 11/18/2023] [Indexed: 11/30/2023]
Abstract
Currently, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) have no effective treatments. Drug repurposing offers a rapid method to meet therapeutic need for ALS and FTD. To identify therapeutic targets associated with ALS and FTD, Mendelian randomization (MR) analysis and colocalization were performed. Genetic instruments were based on transcriptomic and proteomic data for 422 actionable proteins targeted by approved drugs or clinical drug candidates. The publicly available ALS GWAS summary data (including a total of 20,806 ALS cases and 59,804 controls) and FTD GWAS summary data (including a total of 2154 patients with FTD and 4308 controls) were used. Using cis-expression quantitative trait loci and cis-protein quantitative trait loci genetic instruments, we identified several drug targets for repurposing (ALS: MARK3, false-discovery rate (FDR) = 0.043; LTBR, FDR = 0.068) (FTD: HLA-DRB1, FDR = 0.083; ADH5, FDR = 0.056). Our MR study analyzed the actionable druggable proteins and provided potential therapeutic targets for ALS and FTD. Future studies should further elucidate the underlying mechanism of corresponding drug targets in the pathogenesis of ALS and FTD.
Collapse
Affiliation(s)
- Yahui Zhu
- Medical School of Chinese PLA, Beijing, China
- Department of Neurology, the First Medical Center, Chinese PLA General Hospital, Beijing, China
| | - Mao Li
- Department of Neurology, the First Medical Center, Chinese PLA General Hospital, Beijing, China
| | - Hongfen Wang
- Department of Neurology, the First Medical Center, Chinese PLA General Hospital, Beijing, China
| | - Fei Yang
- Department of Neurology, the First Medical Center, Chinese PLA General Hospital, Beijing, China
| | - RongRong Du
- Department of Neurology, the First Medical Center, Chinese PLA General Hospital, Beijing, China
- College of Medicine, Nankai University, Tianjin, China
| | - Xinyuan Pang
- Department of Neurology, the First Medical Center, Chinese PLA General Hospital, Beijing, China
- College of Medicine, Nankai University, Tianjin, China
| | - Jiongming Bai
- Department of Neurology, the First Medical Center, Chinese PLA General Hospital, Beijing, China
- College of Medicine, Nankai University, Tianjin, China
| | - Xusheng Huang
- Medical School of Chinese PLA, Beijing, China.
- Department of Neurology, the First Medical Center, Chinese PLA General Hospital, Beijing, China.
| |
Collapse
|
4
|
Parvizi T, Klotz S, Keritam O, Caliskan H, Imhof S, König T, Haider L, Traub‐Weidinger T, Wagner M, Brunet T, Brugger M, Zimprich A, Rath J, Stögmann E, Gelpi E, Cetin H. Clinical heterogeneity within the ALS-FTD spectrum in a family with a homozygous optineurin mutation. Ann Clin Transl Neurol 2024; 11:1579-1589. [PMID: 38689506 PMCID: PMC11187959 DOI: 10.1002/acn3.52075] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2023] [Revised: 03/24/2024] [Accepted: 04/01/2024] [Indexed: 05/02/2024] Open
Abstract
OBJECTIVE Mutations in the gene encoding for optineurin (OPTN) have been reported in the context of different neurodegenerative diseases including the amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) spectrum. Based on single case reports, neuropathological data in OPTN mutation carriers have revealed transactive response DNA-binding protein 43 kDa (TDP-43) pathology, in addition to accumulations of tau and alpha-synuclein. Herein, we present two siblings from a consanguineous family with a homozygous frameshift mutation in the OPTN gene and different clinical presentations. METHODS Both affected siblings underwent (i) clinical, (ii) neurophysiological, (iii) neuropsychological, (iv) radiological, and (v) laboratory examinations, and (vi) whole-exome sequencing (WES). Postmortem histopathological examination was conducted in the index patient, who deceased at the age of 41. RESULTS The index patient developed rapidly progressing clinical features of upper and lower motor neuron dysfunction as well as apathy and cognitive deterioration at the age of 41. Autopsy revealed an ALS-FTLD pattern associated with prominent neuronal and oligodendroglial TDP-43 pathology, and an atypical limbic 4-repeat tau pathology reminiscent of argyrophilic grain disease. The brother of the index patient exhibited behavioral changes and mnestic deficits at the age of 38 and was diagnosed with behavioral FTD 5 years later, without any evidence of motor neuron dysfunction. WES revealed a homozygous frameshift mutation in the OPTN gene in both siblings (NM_001008212.2: c.1078_1079del; p.Lys360ValfsTer18). INTERPRETATION OPTN mutations can be associated with extensive TDP-43 pathology and limbic-predominant tauopathy and present with a heterogeneous clinical phenotype within the ALS-FTD spectrum within the same family.
Collapse
Affiliation(s)
- Tandis Parvizi
- Department of NeurologyMedical University of ViennaViennaAustria
- Comprehensive Center for Clinical Neurosciences and Mental HealthMedical University of ViennaViennaAustria
| | - Sigrid Klotz
- Comprehensive Center for Clinical Neurosciences and Mental HealthMedical University of ViennaViennaAustria
- Division of Neuropathology and Neurochemistry, Department of NeurologyMedical University of ViennaViennaAustria
| | - Omar Keritam
- Department of NeurologyMedical University of ViennaViennaAustria
- Comprehensive Center for Clinical Neurosciences and Mental HealthMedical University of ViennaViennaAustria
| | - Haluk Caliskan
- Department of NeurologyMedical University of ViennaViennaAustria
| | - Sophie Imhof
- Department of NeurologyMedical University of ViennaViennaAustria
- Comprehensive Center for Clinical Neurosciences and Mental HealthMedical University of ViennaViennaAustria
| | - Theresa König
- Department of NeurologyMedical University of ViennaViennaAustria
- Comprehensive Center for Clinical Neurosciences and Mental HealthMedical University of ViennaViennaAustria
| | - Lukas Haider
- Department of Biomedical Imaging and Image‐Guided TherapyMedical University of ViennaViennaAustria
- Queen Square Multiple Sclerosis Centre, Department of NeuroinflammationUCL Queen Square Institute of Neurology, University College LondonLondonUK
| | - Tatjana Traub‐Weidinger
- Division of Nuclear Medicine, Department of Biomedical Imaging and Image‐Guided TherapyMedical University of ViennaViennaAustria
| | - Matias Wagner
- Institute of Neurogenomics, Helmholtz CentrumMunichGermany
- Institute of Human Genetics, Technical University MunichMunichGermany
| | - Theresa Brunet
- Institute of Human Genetics, Technical University MunichMunichGermany
- Department of Pediatric Neurology, Developmental Medicine and Social Pediatrics, Dr. von Hauner's Children's HospitalUniversity of MunichMunichGermany
| | - Melanie Brugger
- Institute of Human Genetics, Technical University MunichMunichGermany
| | - Alexander Zimprich
- Department of NeurologyMedical University of ViennaViennaAustria
- Comprehensive Center for Clinical Neurosciences and Mental HealthMedical University of ViennaViennaAustria
| | - Jakob Rath
- Department of NeurologyMedical University of ViennaViennaAustria
- Comprehensive Center for Clinical Neurosciences and Mental HealthMedical University of ViennaViennaAustria
| | - Elisabeth Stögmann
- Department of NeurologyMedical University of ViennaViennaAustria
- Comprehensive Center for Clinical Neurosciences and Mental HealthMedical University of ViennaViennaAustria
| | - Ellen Gelpi
- Comprehensive Center for Clinical Neurosciences and Mental HealthMedical University of ViennaViennaAustria
- Division of Neuropathology and Neurochemistry, Department of NeurologyMedical University of ViennaViennaAustria
| | - Hakan Cetin
- Department of NeurologyMedical University of ViennaViennaAustria
- Comprehensive Center for Clinical Neurosciences and Mental HealthMedical University of ViennaViennaAustria
| |
Collapse
|
5
|
Kacem I, Sghaier I, Peverelli S, Abida Y, Ben Brahim H, Ratti A, Nasri A, Ticozzi N, Silani V, Gouider R. Optineurin in patients with Amyotrophic Lateral Sclerosis associated to atypical Parkinsonism in Tunisian population. Amyotroph Lateral Scler Frontotemporal Degener 2024; 25:128-134. [PMID: 37904275 DOI: 10.1080/21678421.2023.2273961] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2023] [Accepted: 10/10/2023] [Indexed: 11/01/2023]
Abstract
Amyotrophic Lateral Sclerosis (ALS) is a heterogeneous disorder and the phenotypic variability goes far beyond the used clinical stratification parameter. Evidence has emerged that ALS may coexist with distinct neurodegenerative diseases in single cases. We aim to study the clinical features of two familial cases of ALS carriers of two distinct variants harbored in the Optineurin (OPTN) gene. We included definite familial ALS followed up in the Department of Neurology of Razi University Hospital, Tunisia, and selected according to Byrne criteria. Preliminary screening for the four main ALS genes (SOD1, C9ORF72, TARDBP, FUS) was conducted. Given the negative results, we proceeded to NGS target-re-sequencing with a custom panel including genes associated with ALS-FTD, Alzheimer's, and Parkinson's diseases. Both families are carriers of two different OPTN variants and they present very different ALS clinical features. The first family comprises two siblings diagnosed with ALS and Corticobasal syndrome (ALS-CBS) at an early age of onset and carriers of OPTN p.E135X in the homozygous state. The proband for the second family was diagnosed with ALS at an early age of onset presenting as progressive muscular atrophy with rapid progression. Genetic analysis revealed the presence of the homozygous variant p.R520H. Our findings highlight the peculiarity of genetic Tunisian drift. Indeed, genes with a recessive mode of inheritance may explain part of ALS diversity in clinical features. Therefore, the screening of the OPTN gene is highly recommended among inbreeding populations such as the Tunisian one.
Collapse
Affiliation(s)
- I Kacem
- Neurology Department, LR18SP03, Razi University Hospital, Tunis, Tunisia
- Faculty of Medicine of Tunis, University of Tunis El Manar, Tunis, Tunisia
- Clinical Investigation Center (CIC) "Neurosciences and Mental Health", Razi Universitary Hospital, Tunis, Tunisia
| | - I Sghaier
- Neurology Department, LR18SP03, Razi University Hospital, Tunis, Tunisia
- Faculty of Medicine of Tunis, University of Tunis El Manar, Tunis, Tunisia
- Clinical Investigation Center (CIC) "Neurosciences and Mental Health", Razi Universitary Hospital, Tunis, Tunisia
| | - S Peverelli
- Department of Neurology and Laboratory of Neuroscience, Istituto Auxologico Italiano, IRCCS, Milan, Italy
| | - Y Abida
- Neurology Department, LR18SP03, Razi University Hospital, Tunis, Tunisia
- Faculty of Medicine of Tunis, University of Tunis El Manar, Tunis, Tunisia
- Clinical Investigation Center (CIC) "Neurosciences and Mental Health", Razi Universitary Hospital, Tunis, Tunisia
| | - H Ben Brahim
- Neurology Department, LR18SP03, Razi University Hospital, Tunis, Tunisia
| | - A Ratti
- Department of Neurology and Laboratory of Neuroscience, Istituto Auxologico Italiano, IRCCS, Milan, Italy
- Department of Medical Biotechnology and Translational Medicine, Università degli Studi di Milano, Milan, Italy, and
| | - A Nasri
- Neurology Department, LR18SP03, Razi University Hospital, Tunis, Tunisia
- Faculty of Medicine of Tunis, University of Tunis El Manar, Tunis, Tunisia
- Clinical Investigation Center (CIC) "Neurosciences and Mental Health", Razi Universitary Hospital, Tunis, Tunisia
| | - N Ticozzi
- Department of Neurology and Laboratory of Neuroscience, Istituto Auxologico Italiano, IRCCS, Milan, Italy
- Department of Pathophysiology and Transplantation, "Dino Ferrari" Center, Università degli Studi di Milano, Milan, Italy
| | - V Silani
- Department of Neurology and Laboratory of Neuroscience, Istituto Auxologico Italiano, IRCCS, Milan, Italy
- Department of Pathophysiology and Transplantation, "Dino Ferrari" Center, Università degli Studi di Milano, Milan, Italy
| | - R Gouider
- Neurology Department, LR18SP03, Razi University Hospital, Tunis, Tunisia
- Faculty of Medicine of Tunis, University of Tunis El Manar, Tunis, Tunisia
- Clinical Investigation Center (CIC) "Neurosciences and Mental Health", Razi Universitary Hospital, Tunis, Tunisia
| |
Collapse
|
6
|
Dey B, Kumar A, Patel AB. Pathomechanistic Networks of Motor System Injury in Amyotrophic Lateral Sclerosis. Curr Neuropharmacol 2024; 22:1778-1806. [PMID: 37622689 PMCID: PMC11284732 DOI: 10.2174/1570159x21666230824091601] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2023] [Revised: 05/25/2023] [Accepted: 06/06/2023] [Indexed: 08/26/2023] Open
Abstract
Amyotrophic Lateral Sclerosis (ALS) is the most common, adult-onset, progressive motor neurodegenerative disorder that results in death within 3 years of the clinical diagnosis. Due to the clinicopathological heterogeneity, any reliable biomarkers for diagnosis or prognosis of ALS have not been identified till date. Moreover, the only three clinically approved treatments are not uniformly effective in slowing the disease progression. Over the last 15 years, there has been a rapid advancement in research on the complex pathomechanistic landscape of ALS that has opened up new avenues for successful clinical translation of targeted therapeutics. Multiple studies suggest that the age-dependent interaction of risk-associated genes with environmental factors and endogenous modifiers is critical to the multi-step process of ALS pathogenesis. In this review, we provide an updated discussion on the dysregulated cross-talk between intracellular homeostasis processes, the unique molecular networks across selectively vulnerable cell types, and the multisystemic nature of ALS pathomechanisms. Importantly, this work highlights the alteration in epigenetic and epitranscriptomic landscape due to gene-environment interactions, which have been largely overlooked in the context of ALS pathology. Finally, we suggest that precision medicine research in ALS will be largely benefitted from the stratification of patient groups based on the clinical phenotype, onset and progression, genome, exposome, and metabolic identities.
Collapse
Affiliation(s)
- Bedaballi Dey
- CSIR-Centre for Cellular and Molecular Biology (CSIR-CCMB), Hyderabad 500007, Telangana, India
- AcSIR-Academy of Scientific and Innovative Research, Ghaziabad 201002, Uttar Pradesh, India
| | - Arvind Kumar
- CSIR-Centre for Cellular and Molecular Biology (CSIR-CCMB), Hyderabad 500007, Telangana, India
- AcSIR-Academy of Scientific and Innovative Research, Ghaziabad 201002, Uttar Pradesh, India
| | - Anant Bahadur Patel
- CSIR-Centre for Cellular and Molecular Biology (CSIR-CCMB), Hyderabad 500007, Telangana, India
- AcSIR-Academy of Scientific and Innovative Research, Ghaziabad 201002, Uttar Pradesh, India
| |
Collapse
|
7
|
Furthmann N, Bader V, Angersbach L, Blusch A, Goel S, Sánchez-Vicente A, Krause LJ, Chaban SA, Grover P, Trinkaus VA, van Well EM, Jaugstetter M, Tschulik K, Damgaard RB, Saft C, Ellrichmann G, Gold R, Koch A, Englert B, Westenberger A, Klein C, Jungbluth L, Sachse C, Behrends C, Glatzel M, Hartl FU, Nakamura K, Christine CW, Huang EJ, Tatzelt J, Winklhofer KF. NEMO reshapes the α-Synuclein aggregate interface and acts as an autophagy adapter by co-condensation with p62. Nat Commun 2023; 14:8368. [PMID: 38114471 PMCID: PMC10730909 DOI: 10.1038/s41467-023-44033-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2023] [Accepted: 11/28/2023] [Indexed: 12/21/2023] Open
Abstract
NEMO is a ubiquitin-binding protein which regulates canonical NF-κB pathway activation in innate immune signaling, cell death regulation and host-pathogen interactions. Here we identify an NF-κB-independent function of NEMO in proteostasis regulation by promoting autophagosomal clearance of protein aggregates. NEMO-deficient cells accumulate misfolded proteins upon proteotoxic stress and are vulnerable to proteostasis challenges. Moreover, a patient with a mutation in the NEMO-encoding IKBKG gene resulting in defective binding of NEMO to linear ubiquitin chains, developed a widespread mixed brain proteinopathy, including α-synuclein, tau and TDP-43 pathology. NEMO amplifies linear ubiquitylation at α-synuclein aggregates and promotes the local concentration of p62 into foci. In vitro, NEMO lowers the threshold concentrations required for ubiquitin-dependent phase transition of p62. In summary, NEMO reshapes the aggregate surface for efficient autophagosomal clearance by providing a mobile phase at the aggregate interphase favoring co-condensation with p62.
Collapse
Affiliation(s)
- Nikolas Furthmann
- Department Molecular Cell Biology, Institute of Biochemistry and Pathobiochemistry, Ruhr University Bochum, 44801, Bochum, Germany
| | - Verian Bader
- Department Molecular Cell Biology, Institute of Biochemistry and Pathobiochemistry, Ruhr University Bochum, 44801, Bochum, Germany
- Department Biochemistry of Neurodegenerative Diseases, Institute of Biochemistry and Pathobiochemistry, Ruhr University Bochum, 44801, Bochum, Germany
| | - Lena Angersbach
- Department Molecular Cell Biology, Institute of Biochemistry and Pathobiochemistry, Ruhr University Bochum, 44801, Bochum, Germany
| | - Alina Blusch
- Department of Neurology, St Josef Hospital, Ruhr University Bochum, 44791, Bochum, Germany
| | - Simran Goel
- Department Molecular Cell Biology, Institute of Biochemistry and Pathobiochemistry, Ruhr University Bochum, 44801, Bochum, Germany
| | - Ana Sánchez-Vicente
- Department Molecular Cell Biology, Institute of Biochemistry and Pathobiochemistry, Ruhr University Bochum, 44801, Bochum, Germany
| | - Laura J Krause
- Department Molecular Cell Biology, Institute of Biochemistry and Pathobiochemistry, Ruhr University Bochum, 44801, Bochum, Germany
- Cluster of Excellence RESOLV, 44801, Bochum, Germany
| | - Sarah A Chaban
- Department Molecular Cell Biology, Institute of Biochemistry and Pathobiochemistry, Ruhr University Bochum, 44801, Bochum, Germany
| | - Prerna Grover
- Department Biochemistry of Neurodegenerative Diseases, Institute of Biochemistry and Pathobiochemistry, Ruhr University Bochum, 44801, Bochum, Germany
| | - Victoria A Trinkaus
- Department of Cellular Biochemistry, Max Planck Institute of Biochemistry, 82152, Martinsried, Germany
| | - Eva M van Well
- Department Molecular Cell Biology, Institute of Biochemistry and Pathobiochemistry, Ruhr University Bochum, 44801, Bochum, Germany
| | - Maximilian Jaugstetter
- Analytical Chemistry II, Faculty of Chemistry and Biochemistry, Ruhr University Bochum, 44801, Bochum, Germany
| | - Kristina Tschulik
- Cluster of Excellence RESOLV, 44801, Bochum, Germany
- Analytical Chemistry II, Faculty of Chemistry and Biochemistry, Ruhr University Bochum, 44801, Bochum, Germany
| | - Rune Busk Damgaard
- Department of Biotechnology and Biomedicine, Technical University of Denmark, 2800, Kongens Lyngby, Denmark
| | - Carsten Saft
- Department of Neurology, St Josef Hospital, Ruhr University Bochum, 44791, Bochum, Germany
| | - Gisa Ellrichmann
- Department of Neurology, St Josef Hospital, Ruhr University Bochum, 44791, Bochum, Germany
- Department of Neurology, Klinikum Dortmund, University Witten/Herdecke, 44135, Dortmund, Germany
| | - Ralf Gold
- Department of Neurology, St Josef Hospital, Ruhr University Bochum, 44791, Bochum, Germany
| | - Arend Koch
- Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Neuropathology, Charitéplatz 1, 10117, Berlin, Germany
| | - Benjamin Englert
- Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Neuropathology, Charitéplatz 1, 10117, Berlin, Germany
- Center for Neuropathology and Prion Research, Ludwig-Maximilians University, 81377, Munich, Germany
| | - Ana Westenberger
- Institute of Neurogenetics, University of Lübeck, Lübeck, Germany
| | - Christine Klein
- Institute of Neurogenetics, University of Lübeck, Lübeck, Germany
| | - Lisa Jungbluth
- Ernst-Ruska Centre for Microscopy and Spectroscopy with Electrons (ER-C-3/Structural Biology), Forschungszentrum Jülich, Jülich, Germany
- Institute for Biological Information Processing (IBI-6/Cellular Structural Biology), Forschungszentrum Jülich, Jülich, Germany
| | - Carsten Sachse
- Ernst-Ruska Centre for Microscopy and Spectroscopy with Electrons (ER-C-3/Structural Biology), Forschungszentrum Jülich, Jülich, Germany
- Institute for Biological Information Processing (IBI-6/Cellular Structural Biology), Forschungszentrum Jülich, Jülich, Germany
- Department of Biology, Heinrich Heine University, Düsseldorf, Germany
| | - Christian Behrends
- Munich Cluster for Systems Neurology, Faculty of Medicine, Ludwig-Maximilians-Universität München, Munich, Germany
| | - Markus Glatzel
- Institute of Neuropathology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20251, Hamburg, Germany
| | - F Ulrich Hartl
- Department of Cellular Biochemistry, Max Planck Institute of Biochemistry, 82152, Martinsried, Germany
- Munich Cluster for Systems Neurology (SyNergy), 81377, Munich, Germany
| | - Ken Nakamura
- Gladstone Institute of Neurological Disease, Gladstone Institutes, San Francisco, CA, USA
- Department of Neurology, University of California, San Francisco, CA, USA
| | - Chadwick W Christine
- Department of Neurology, University of California, San Francisco, CA, USA
- Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA
| | - Eric J Huang
- Department of Neurology, University of California, San Francisco, CA, USA
- Department of Pathology, University of California, San Francisco, CA, USA
| | - Jörg Tatzelt
- Department Biochemistry of Neurodegenerative Diseases, Institute of Biochemistry and Pathobiochemistry, Ruhr University Bochum, 44801, Bochum, Germany
- Cluster of Excellence RESOLV, 44801, Bochum, Germany
| | - Konstanze F Winklhofer
- Department Molecular Cell Biology, Institute of Biochemistry and Pathobiochemistry, Ruhr University Bochum, 44801, Bochum, Germany.
- Cluster of Excellence RESOLV, 44801, Bochum, Germany.
| |
Collapse
|
8
|
Riku Y, Yoshida M, Iwasaki Y, Sobue G, Katsuno M, Ishigaki S. TDP-43 Proteinopathy and Tauopathy: Do They Have Pathomechanistic Links? Int J Mol Sci 2022; 23:ijms232415755. [PMID: 36555399 PMCID: PMC9779029 DOI: 10.3390/ijms232415755] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2022] [Revised: 12/07/2022] [Accepted: 12/07/2022] [Indexed: 12/14/2022] Open
Abstract
Transactivation response DNA binding protein 43 kDa (TDP-43) and tau are major pathological proteins of neurodegenerative disorders, of which neuronal and glial aggregates are pathological hallmarks. Interestingly, accumulating evidence from neuropathological studies has shown that comorbid TDP-43 pathology is observed in a subset of patients with tauopathies, and vice versa. The concomitant pathology often spreads in a disease-specific manner and has morphological characteristics in each primary disorder. The findings from translational studies have suggested that comorbid TDP-43 or tau pathology has clinical impacts and that the comorbid pathology is not a bystander, but a part of the disease process. Shared genetic risk factors or molecular abnormalities between TDP-43 proteinopathies and tauopathies, and direct interactions between TDP-43 and tau aggregates, have been reported. Further investigations to clarify the pathogenetic factors that are shared by a broad spectrum of neurodegenerative disorders will establish key therapeutic targets.
Collapse
Affiliation(s)
- Yuichi Riku
- Institute for Medical Science of Aging, Aichi Medical University, Nagakute 480-1195, Japan
- Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya 744-8550, Japan
- Correspondence: or
| | - Mari Yoshida
- Institute for Medical Science of Aging, Aichi Medical University, Nagakute 480-1195, Japan
| | - Yasushi Iwasaki
- Institute for Medical Science of Aging, Aichi Medical University, Nagakute 480-1195, Japan
| | - Gen Sobue
- Graduate School of Medicine, Aichi Medical University, Nagakute 480-1195, Japan
| | - Masahisa Katsuno
- Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya 744-8550, Japan
- Department of Clinical Research Education, Nagoya University Graduate School of Medicine, Nagoya 744-8550, Japan
| | - Shinsuke Ishigaki
- Molecular Neuroscience Research Center, Shiga University of Medical Science, Otsu 520-2192, Japan
| |
Collapse
|
9
|
Jetto CT, Nambiar A, Manjithaya R. Mitophagy and Neurodegeneration: Between the Knowns and the Unknowns. Front Cell Dev Biol 2022; 10:837337. [PMID: 35392168 PMCID: PMC8981085 DOI: 10.3389/fcell.2022.837337] [Citation(s) in RCA: 16] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2021] [Accepted: 01/24/2022] [Indexed: 12/11/2022] Open
Abstract
Macroautophagy (henceforth autophagy) an evolutionary conserved intracellular pathway, involves lysosomal degradation of damaged and superfluous cytosolic contents to maintain cellular homeostasis. While autophagy was initially perceived as a bulk degradation process, a surfeit of studies in the last 2 decades has revealed that it can also be selective in choosing intracellular constituents for degradation. In addition to the core autophagy machinery, these selective autophagy pathways comprise of distinct molecular players that are involved in the capture of specific cargoes. The diverse organelles that are degraded by selective autophagy pathways are endoplasmic reticulum (ERphagy), lysosomes (lysophagy), mitochondria (mitophagy), Golgi apparatus (Golgiphagy), peroxisomes (pexophagy) and nucleus (nucleophagy). Among these, the main focus of this review is on the selective autophagic pathway involved in mitochondrial turnover called mitophagy. The mitophagy pathway encompasses diverse mechanisms involving a complex interplay of a multitude of proteins that confers the selective recognition of damaged mitochondria and their targeting to degradation via autophagy. Mitophagy is triggered by cues that signal the mitochondrial damage such as disturbances in mitochondrial fission-fusion dynamics, mitochondrial membrane depolarisation, enhanced ROS production, mtDNA damage as well as developmental cues such as erythrocyte maturation, removal of paternal mitochondria, cardiomyocyte maturation and somatic cell reprogramming. As research on the mechanistic aspects of this complex pathway is progressing, emerging roles of new players such as the NIPSNAP proteins, Miro proteins and ER-Mitochondria contact sites (ERMES) are being explored. Although diverse aspects of this pathway are being investigated in depth, several outstanding questions such as distinct molecular players of basal mitophagy, selective dominance of a particular mitophagy adapter protein over the other in a given physiological condition, molecular mechanism of how specific disease mutations affect this pathway remain to be addressed. In this review, we aim to give an overview with special emphasis on molecular and signalling pathways of mitophagy and its dysregulation in neurodegenerative disorders.
Collapse
Affiliation(s)
- Cuckoo Teresa Jetto
- Autophagy Laboratory, Molecular Biology and Genetics Unit, Jawaharlal Nehru Centre for Advanced Scientific Research, Bengaluru, India
| | - Akshaya Nambiar
- Autophagy Laboratory, Molecular Biology and Genetics Unit, Jawaharlal Nehru Centre for Advanced Scientific Research, Bengaluru, India
| | - Ravi Manjithaya
- Autophagy Laboratory, Molecular Biology and Genetics Unit, Jawaharlal Nehru Centre for Advanced Scientific Research, Bengaluru, India
- Neuroscience Unit, Jawaharlal Nehru Centre for Advanced Scientific Research, Bengaluru, India
- *Correspondence: Ravi Manjithaya,
| |
Collapse
|
10
|
Petrozziello T, Amaral AC, Dujardin S, Farhan SMK, Chan J, Trombetta BA, Kivisäkk P, Mills AN, Bordt EA, Kim SE, Dooley PM, Commins C, Connors TR, Oakley DH, Ghosal A, Gomez-Isla T, Hyman BT, Arnold SE, Spires-Jones T, Cudkowicz ME, Berry JD, Sadri-Vakili G. Novel genetic variants in MAPT and alterations in tau phosphorylation in amyotrophic lateral sclerosis post-mortem motor cortex and cerebrospinal fluid. Brain Pathol 2021; 32:e13035. [PMID: 34779076 PMCID: PMC8877756 DOI: 10.1111/bpa.13035] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2021] [Revised: 09/22/2021] [Accepted: 10/28/2021] [Indexed: 12/12/2022] Open
Abstract
Although the molecular mechanisms underlying amyotrophic lateral sclerosis (ALS) are not yet fully understood, several studies report alterations in tau phosphorylation in both sporadic and familial ALS. Recently, we have demonstrated that phosphorylated tau at S396 (pTau‐S396) is mislocalized to synapses in ALS motor cortex (mCTX) and contributes to mitochondrial dysfunction. Here, we demonstrate that while there was no overall increase in total tau, pTau‐S396, and pTau‐S404 in ALS post‐mortem mCTX, total tau and pTau‐S396 were increased in C9ORF72‐ALS. Additionally, there was a significant decrease in pTau‐T181 in ALS mCTX compared controls. Furthermore, we leveraged the ALS Knowledge Portal and Project MinE data sets and identified ALS‐specific genetic variants across MAPT, the gene encoding tau. Lastly, assessment of cerebrospinal fluid (CSF) samples revealed a significant increase in total tau levels in bulbar‐onset ALS together with a decrease in CSF pTau‐T181:tau ratio in all ALS samples, as reported previously. While increases in CSF tau levels correlated with a faster disease progression as measured by the revised ALS functional rating scale (ALSFRS‐R), decreases in CSF pTau‐T181:tau ratio correlated with a slower disease progression, suggesting that CSF total tau and pTau‐T181 ratio may serve as biomarkers of disease in ALS. Our findings highlight the potential role of pTau‐T181 in ALS, as decreases in CSF pTau‐T181:tau ratio may reflect the significant decrease in pTau‐T181 in post‐mortem mCTX. Taken together, these results indicate that tau phosphorylation is altered in ALS post‐mortem mCTX as well as in CSF and, importantly, the newly described pathogenic or likely pathogenic variants identified in MAPT in this study are adjacent to T181 and S396 phosphorylation sites further highlighting the potential role of these tau functional domains in ALS. Although the molecular mechanisms underlying amyotrophic lateral sclerosis (ALS) are not yet fully understood, recent studies report alterations in tau phosphorylation in ALS. Our study builds on these findings and demonstrates that tau phosphorylation is altered in post‐mortem ALS motor cortex and highlights new and ALS‐specific variants in MAPT, the gene encoding tau. Lastly, we report alterations in phosphorylated tau in ALS cerebrospinal fluid that may function as a predictive biomarker for ALS.![]()
Collapse
Affiliation(s)
- Tiziana Petrozziello
- Sean M. Healey & AMG Center for ALS at Mass General, Massachusetts General Hospital, Boston, Massachusetts, USA
| | - Ana C Amaral
- Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
| | - Simon Dujardin
- Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
| | - Sali M K Farhan
- Analytic and Translational Genetics Unit, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.,Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA
| | - James Chan
- Biostatistics Center, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA
| | - Bianca A Trombetta
- Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
| | - Pia Kivisäkk
- Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
| | - Alexandra N Mills
- Sean M. Healey & AMG Center for ALS at Mass General, Massachusetts General Hospital, Boston, Massachusetts, USA
| | - Evan A Bordt
- Department of Pediatrics, Lurie Center for Autism, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
| | - Spencer E Kim
- Sean M. Healey & AMG Center for ALS at Mass General, Massachusetts General Hospital, Boston, Massachusetts, USA
| | - Patrick M Dooley
- Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
| | - Caitlin Commins
- Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
| | - Theresa R Connors
- Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
| | - Derek H Oakley
- Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
| | - Anubrata Ghosal
- Sean M. Healey & AMG Center for ALS at Mass General, Massachusetts General Hospital, Boston, Massachusetts, USA
| | - Teresa Gomez-Isla
- Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
| | - Bradley T Hyman
- Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
| | - Steven E Arnold
- Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
| | - Tara Spires-Jones
- Centre for Discovery Brain Sciences, UK Dementia Research Institute, University of Edinburgh, UK
| | - Merit E Cudkowicz
- Sean M. Healey & AMG Center for ALS at Mass General, Massachusetts General Hospital, Boston, Massachusetts, USA
| | - James D Berry
- Sean M. Healey & AMG Center for ALS at Mass General, Massachusetts General Hospital, Boston, Massachusetts, USA
| | - Ghazaleh Sadri-Vakili
- Sean M. Healey & AMG Center for ALS at Mass General, Massachusetts General Hospital, Boston, Massachusetts, USA
| |
Collapse
|
11
|
Petrozziello T, Bordt EA, Mills AN, Kim SE, Sapp E, Devlin BA, Obeng-Marnu AA, Farhan SMK, Amaral AC, Dujardin S, Dooley PM, Henstridge C, Oakley DH, Neueder A, Hyman BT, Spires-Jones TL, Bilbo SD, Vakili K, Cudkowicz ME, Berry JD, DiFiglia M, Silva MC, Haggarty SJ, Sadri-Vakili G. Targeting Tau Mitigates Mitochondrial Fragmentation and Oxidative Stress in Amyotrophic Lateral Sclerosis. Mol Neurobiol 2021; 59:683-702. [PMID: 34757590 DOI: 10.1007/s12035-021-02557-w] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2021] [Accepted: 09/09/2021] [Indexed: 11/29/2022]
Abstract
Understanding the mechanisms underlying amyotrophic lateral sclerosis (ALS) is crucial for the development of new therapies. Previous studies have demonstrated that mitochondrial dysfunction is a key pathogenetic event in ALS. Interestingly, studies in Alzheimer's disease (AD) post-mortem brain and animal models link alterations in mitochondrial function to interactions between hyperphosphorylated tau and dynamin-related protein 1 (DRP1), the GTPase involved in mitochondrial fission. Recent evidence suggest that tau may be involved in ALS pathogenesis, therefore, we sought to determine whether hyperphosphorylated tau may lead to mitochondrial fragmentation and dysfunction in ALS and whether reducing tau may provide a novel therapeutic approach. Our findings demonstrated that pTau-S396 is mis-localized to synapses in post-mortem motor cortex (mCTX) across ALS subtypes. Additionally, the treatment with ALS synaptoneurosomes (SNs), enriched in pTau-S396, increased oxidative stress, induced mitochondrial fragmentation, and altered mitochondrial connectivity without affecting cell survival in vitro. Furthermore, pTau-S396 interacted with DRP1, and similar to pTau-S396, DRP1 accumulated in SNs across ALS subtypes, suggesting increases in mitochondrial fragmentation in ALS. As previously reported, electron microscopy revealed a significant decrease in mitochondria density and length in ALS mCTX. Lastly, reducing tau levels with QC-01-175, a selective tau degrader, prevented ALS SNs-induced mitochondrial fragmentation and oxidative stress in vitro. Collectively, our findings suggest that increases in pTau-S396 may lead to mitochondrial fragmentation and oxidative stress in ALS and decreasing tau may provide a novel strategy to mitigate mitochondrial dysfunction in ALS. pTau-S396 mis-localizes to synapses in ALS. ALS synaptoneurosomes (SNs), enriched in pTau-S396, increase oxidative stress and induce mitochondrial fragmentation in vitro. pTau-S396 interacts with the pro-fission GTPase DRP1 in ALS. Reducing tau with a selective degrader, QC-01-175, mitigates ALS SNs-induced mitochondrial fragmentation and increases in oxidative stress in vitro.
Collapse
Affiliation(s)
- Tiziana Petrozziello
- Sean M. Healey & AMG Center for ALS at Mass General, Massachusetts General Hospital, Boston, MA, 02129, USA
| | - Evan A Bordt
- Department of Pediatrics, Lurie Center for Autism, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02129, USA
| | - Alexandra N Mills
- Sean M. Healey & AMG Center for ALS at Mass General, Massachusetts General Hospital, Boston, MA, 02129, USA
| | - Spencer E Kim
- Sean M. Healey & AMG Center for ALS at Mass General, Massachusetts General Hospital, Boston, MA, 02129, USA
| | - Ellen Sapp
- Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, 02129, USA
| | - Benjamin A Devlin
- Department of Psychology and Neuroscience, Duke University, Durham, NC, USA
| | - Abigail A Obeng-Marnu
- Department of Pediatrics, Lurie Center for Autism, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02129, USA
| | - Sali M K Farhan
- Analytic and Translational Genetics Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02114, USA.,Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, 7 Cambridge Center, Cambridge, MA, 02142, USA
| | - Ana C Amaral
- Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, 02129, USA
| | - Simon Dujardin
- Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, 02129, USA
| | - Patrick M Dooley
- Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, 02129, USA
| | - Christopher Henstridge
- Centre for Discovery Brain Sciences, UK Dementia Research Institute, University of Edinburgh, Edinburgh, UK.,Division of Systems Medicine, Neuroscience, Ninewells hospital & Medical School, University of Dundee, Dundee, UK
| | - Derek H Oakley
- Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, 02129, USA
| | - Andreas Neueder
- Department of Neurology, Ulm University, 89081, Ulm, Germany
| | - Bradley T Hyman
- Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, 02129, USA
| | - Tara L Spires-Jones
- Centre for Discovery Brain Sciences, UK Dementia Research Institute, University of Edinburgh, Edinburgh, UK
| | - Staci D Bilbo
- Department of Pediatrics, Lurie Center for Autism, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02129, USA.,Department of Psychology and Neuroscience, Duke University, Durham, NC, USA
| | - Khashayar Vakili
- Department of Surgery, Boston Children's Hospital, Boston, MA, 02125, USA
| | - Merit E Cudkowicz
- Sean M. Healey & AMG Center for ALS at Mass General, Massachusetts General Hospital, Boston, MA, 02129, USA
| | - James D Berry
- Sean M. Healey & AMG Center for ALS at Mass General, Massachusetts General Hospital, Boston, MA, 02129, USA
| | - Marian DiFiglia
- Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, 02129, USA
| | - M Catarina Silva
- Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, 02129, USA.,Chemical Neurobiology Laboratory, Center for Genomic Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA
| | - Stephen J Haggarty
- Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, 02129, USA.,Chemical Neurobiology Laboratory, Center for Genomic Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA.,Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, 02114, USA
| | - Ghazaleh Sadri-Vakili
- Sean M. Healey & AMG Center for ALS at Mass General, Massachusetts General Hospital, Boston, MA, 02129, USA. .,MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Bldg 114 16th Street, R2200, Charlestown, MA, 02129, USA.
| |
Collapse
|
12
|
Gotkine M, de Majo M, Wong CH, Topp SD, Michaelson-Cohen R, Epsztejn-Litman S, Eiges R, Y YL, Kanaan M, Shaked HM, Alahmady N, Vance C, Newhouse SJ, Breen G, Nishimura AL, Shaw CE, Smith BN. A recessive S174X mutation in Optineurin causes amyotrophic lateral sclerosis through a loss of function via allele-specific nonsense-mediated decay. Neurobiol Aging 2021; 106:351.e1-351.e6. [PMID: 34272080 DOI: 10.1016/j.neurobiolaging.2021.05.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2020] [Revised: 04/13/2021] [Accepted: 05/13/2021] [Indexed: 10/21/2022]
Abstract
Loss of function (LoF) mutations in Optineurin can cause recessive amyotrophic lateral sclerosis (ALS) with some heterozygous LoF mutations associated with dominant ALS. The molecular mechanisms underlying the variable inheritance pattern associated with OPTN mutations have remained elusive. We identified that affected members of a consanguineous Middle Eastern ALS kindred possessed a novel homozygous p.S174X OPTN mutation. Analysis of these primary fibroblast lines from family members identified that the p.S174X mutation reduces OPTN mRNA expression in an allele-dependent fashion by nonsense mediated decay. Western blotting correlated a reduced expression in heterozygote carriers but a complete absence of OPTN protein in the homozygous carrier. This data suggests that the p.S174X truncation mutation causes recessive ALS through LoF. However, functional analysis detected a significant increase in mitophagy markers TOM20 and COXIV, and higher rates of mitochondrial respiration and ATP levels in heterozygous carriers only. This suggests that heterozygous LoF OPTN mutations may not be causative in a Mendelian manner but may potentially behave as contributory ALS risk factors.
Collapse
Affiliation(s)
- Marc Gotkine
- Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK; Department of Neurology, The Agnes Ginges Center for Human Neurogenetics, Hadassah Medical Organization and Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel
| | - Martina de Majo
- Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK
| | - Chun Hao Wong
- Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK
| | - Simon D Topp
- Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK; United Kingdom Dementia Research Institute Centre, King's College London, London, UK
| | - Rachel Michaelson-Cohen
- Medical Genetics Institute, Department of Obstetrics & Gynecology, Shaare Zedek Medical Center affiliated with the Hebrew University School of Medicine, Jerusalem, Israel
| | - Silvina Epsztejn-Litman
- Medical Genetics Institute, Department of Obstetrics & Gynecology, Shaare Zedek Medical Center affiliated with the Hebrew University School of Medicine, Jerusalem, Israel
| | - Rachel Eiges
- Medical Genetics Institute, Department of Obstetrics & Gynecology, Shaare Zedek Medical Center affiliated with the Hebrew University School of Medicine, Jerusalem, Israel
| | - Yossef Lerner Y
- Department of Neurology, The Agnes Ginges Center for Human Neurogenetics, Hadassah Medical Organization and Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel
| | - Moein Kanaan
- Hereditary Research Laboratory, Bethlehem University, Jerusalem, Israel
| | - Hagar Mor Shaked
- Department of Genetics, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
| | - Nada Alahmady
- Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK; Department of Biology, Imam Abdulrahman bin Faisal University, Dammam, Saudi Arabia
| | - Caroline Vance
- Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK
| | - Stephen J Newhouse
- Department of Biostatistics and Health Informatics, King's College London, London, UK
| | - Gerome Breen
- Social, Genetic & Developmental Psychiatry Centre, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK
| | - Agnes L Nishimura
- Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK
| | - Christopher E Shaw
- Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK; United Kingdom Dementia Research Institute Centre, King's College London, London, UK
| | - Bradley N Smith
- Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK; Stem Cell Research Laboratory, Medical Genetics Institute, Shaare Zedek Medical Center affiliated with the Hebrew University School of Medicine, Jerusalem, Israel.
| |
Collapse
|
13
|
Nolan M, Barbagallo P, Turner MR, Keogh MJ, Chinnery PF, Talbot K, Ansorge O. Isolated homozygous R217X OPTN mutation causes knock-out of functional C-terminal optineurin domains and associated oligodendrogliopathy-dominant ALS-TDP. J Neurol Neurosurg Psychiatry 2021; 92:1022-1024. [PMID: 33727253 PMCID: PMC8372379 DOI: 10.1136/jnnp-2020-325803] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/14/2020] [Revised: 01/28/2021] [Accepted: 02/02/2021] [Indexed: 11/28/2022]
Affiliation(s)
- Matthew Nolan
- Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, Oxfordshire, UK
| | - Paola Barbagallo
- Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, Oxfordshire, UK
| | - Martin R Turner
- Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, Oxfordshire, UK
| | - Michael John Keogh
- Biosciences Institute, Newcastle University, Newcastle upon Tyne, Tyne and Wear, UK
| | - Patrick F Chinnery
- Department of Clinical Neurosciences, MRC Mitochondrial Biology Unit, Cambridge, Cambridgeshire, UK
| | - Kevin Talbot
- Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, Oxfordshire, UK
| | - Olaf Ansorge
- Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, Oxfordshire, UK
| |
Collapse
|
14
|
Oliveira LM, Rastin T, Nimmo GA, Ross JP, Dion PA, Zhang M, Nevay DL, Arkadir D, Gotkine M, Barnett C, Shoesmith CL, Zimran A, Rogaeva EA, Zinman L, Rouleau GA, Gan-Or Z, Amato D, Kalia LV. Occurrence of Amyotrophic Lateral Sclerosis in Type 1 Gaucher Disease. Neurol Genet 2021; 7:e600. [PMID: 34017912 PMCID: PMC8130998 DOI: 10.1212/nxg.0000000000000600] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2021] [Accepted: 04/23/2021] [Indexed: 12/23/2022]
Abstract
OBJECTIVE To report the association between type 1 Gaucher disease (GD1) and amyotrophic lateral sclerosis (ALS) in 3 unrelated families and to explore whether GBA variants influence the risk of ALS. METHODS We conducted retrospective chart reviews of patients with GD1 or their family members diagnosed with ALS. To further investigate whether there is an association between ALS and GD, we performed exploratory analyses for the presence of GBA variants in 3 ALS cohorts from Toronto (Canada), Montreal (Canada), and Project MinE (international), totaling 4,653 patients with ALS and 1,832 controls. RESULTS We describe 2 patients with GD1 and 1 obligate GBA mutation carrier (mother of GD1 patient) with ALS. We identified 0 and 8 GBA carriers in the Toronto and Montreal cohorts, respectively. The frequencies of GBA variants in patients with ALS in the Montreal and Project MinE cohorts were similar to those of Project MinE controls or Genome Aggregation Database population controls. CONCLUSIONS The occurrence of ALS in biallelic or monoallelic GBA mutation carriers described here, in addition to common pathogenic pathways shared by GD1 and ALS, suggests that GBA variants could influence ALS risk. However, analyses of GBA variants in ALS cohorts did not reveal a meaningful association. Examination of larger cohorts and neuropathologic studies will be required to elucidate whether patients with GD1 are indeed at increased risk for ALS.
Collapse
Affiliation(s)
| | | | - Graeme A.M. Nimmo
- From the Krembil Research Institute (L.M.O., L.V.K.), Toronto Western Hospital, University Health Network, Ontario; Djavad Mowafaghian Centre for Brain Health (T.R.), Division of Neurology, Department of Medicine, University of British Columbia, Vancouver; Mark Feedman and Judy Jacobs Program for Gaucher Disease (G.A.M.N., D. Amato, L.V.K.), Mount Sinai Hospital; Fred A. Litwin Family Centre for Genetic Medicine (G.A.M.N., D.-L.N.), Department of Medicine, Mount Sinai Hospital and Toronto General Hospital, University Health Network, University of Toronto, Ontario; Department of Human Genetics (J.P.R., P.A.D., G.A.R., Z.G.-O.), Montreal Neurological Institute and Hospital (J.P.R., P.A.D., G.A.R., Z.G.-O.), and Department of Neurology and Neurosurgery (P.A.D., G.A.R., Z.G.-O.), McGill University, Quebec; Tanz Centre for Research in Neurodegenerative Diseases (M.Z., E.A.R., L.V.K.), University of Toronto, Ontario, Canada; Shanghai First Rehabilitation Hospital (M.Z.), School of Medicine, Clinical Center for Brain and Spinal Cord Research (M.Z.), and Institute for Advanced Study (M.Z.), Tongji University, Shanghai, China; Department of Neurology (D. Arkadir, M.G.), Hadassah Medical Center, Hebrew University, Jerusalem, Israel; Ellen and Martin Prosserman Centre for Neuromuscular Diseases (C.B.), Division of Neurology, Department of Medicine, Toronto General Hospital, University Health Network, University of Toronto; London Health Sciences Centre (C.L.S.), London, Ontario, Canada; Gaucher Unit (A.Z.), Shaare Zedek Medical Center, Hadassah Medical School, Hebrew University, Jerusalem, Israel; Division of Neurology (L.Z.), Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto; and Edmond J. Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Clinic (L.V.K.), Division of Neurology, Department of Medicine, Toronto Western Hospital, University Health Network, University of Toronto, Ontario, Canada
| | - Jay P. Ross
- From the Krembil Research Institute (L.M.O., L.V.K.), Toronto Western Hospital, University Health Network, Ontario; Djavad Mowafaghian Centre for Brain Health (T.R.), Division of Neurology, Department of Medicine, University of British Columbia, Vancouver; Mark Feedman and Judy Jacobs Program for Gaucher Disease (G.A.M.N., D. Amato, L.V.K.), Mount Sinai Hospital; Fred A. Litwin Family Centre for Genetic Medicine (G.A.M.N., D.-L.N.), Department of Medicine, Mount Sinai Hospital and Toronto General Hospital, University Health Network, University of Toronto, Ontario; Department of Human Genetics (J.P.R., P.A.D., G.A.R., Z.G.-O.), Montreal Neurological Institute and Hospital (J.P.R., P.A.D., G.A.R., Z.G.-O.), and Department of Neurology and Neurosurgery (P.A.D., G.A.R., Z.G.-O.), McGill University, Quebec; Tanz Centre for Research in Neurodegenerative Diseases (M.Z., E.A.R., L.V.K.), University of Toronto, Ontario, Canada; Shanghai First Rehabilitation Hospital (M.Z.), School of Medicine, Clinical Center for Brain and Spinal Cord Research (M.Z.), and Institute for Advanced Study (M.Z.), Tongji University, Shanghai, China; Department of Neurology (D. Arkadir, M.G.), Hadassah Medical Center, Hebrew University, Jerusalem, Israel; Ellen and Martin Prosserman Centre for Neuromuscular Diseases (C.B.), Division of Neurology, Department of Medicine, Toronto General Hospital, University Health Network, University of Toronto; London Health Sciences Centre (C.L.S.), London, Ontario, Canada; Gaucher Unit (A.Z.), Shaare Zedek Medical Center, Hadassah Medical School, Hebrew University, Jerusalem, Israel; Division of Neurology (L.Z.), Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto; and Edmond J. Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Clinic (L.V.K.), Division of Neurology, Department of Medicine, Toronto Western Hospital, University Health Network, University of Toronto, Ontario, Canada
| | - Patrick A. Dion
- From the Krembil Research Institute (L.M.O., L.V.K.), Toronto Western Hospital, University Health Network, Ontario; Djavad Mowafaghian Centre for Brain Health (T.R.), Division of Neurology, Department of Medicine, University of British Columbia, Vancouver; Mark Feedman and Judy Jacobs Program for Gaucher Disease (G.A.M.N., D. Amato, L.V.K.), Mount Sinai Hospital; Fred A. Litwin Family Centre for Genetic Medicine (G.A.M.N., D.-L.N.), Department of Medicine, Mount Sinai Hospital and Toronto General Hospital, University Health Network, University of Toronto, Ontario; Department of Human Genetics (J.P.R., P.A.D., G.A.R., Z.G.-O.), Montreal Neurological Institute and Hospital (J.P.R., P.A.D., G.A.R., Z.G.-O.), and Department of Neurology and Neurosurgery (P.A.D., G.A.R., Z.G.-O.), McGill University, Quebec; Tanz Centre for Research in Neurodegenerative Diseases (M.Z., E.A.R., L.V.K.), University of Toronto, Ontario, Canada; Shanghai First Rehabilitation Hospital (M.Z.), School of Medicine, Clinical Center for Brain and Spinal Cord Research (M.Z.), and Institute for Advanced Study (M.Z.), Tongji University, Shanghai, China; Department of Neurology (D. Arkadir, M.G.), Hadassah Medical Center, Hebrew University, Jerusalem, Israel; Ellen and Martin Prosserman Centre for Neuromuscular Diseases (C.B.), Division of Neurology, Department of Medicine, Toronto General Hospital, University Health Network, University of Toronto; London Health Sciences Centre (C.L.S.), London, Ontario, Canada; Gaucher Unit (A.Z.), Shaare Zedek Medical Center, Hadassah Medical School, Hebrew University, Jerusalem, Israel; Division of Neurology (L.Z.), Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto; and Edmond J. Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Clinic (L.V.K.), Division of Neurology, Department of Medicine, Toronto Western Hospital, University Health Network, University of Toronto, Ontario, Canada
| | - Ming Zhang
- From the Krembil Research Institute (L.M.O., L.V.K.), Toronto Western Hospital, University Health Network, Ontario; Djavad Mowafaghian Centre for Brain Health (T.R.), Division of Neurology, Department of Medicine, University of British Columbia, Vancouver; Mark Feedman and Judy Jacobs Program for Gaucher Disease (G.A.M.N., D. Amato, L.V.K.), Mount Sinai Hospital; Fred A. Litwin Family Centre for Genetic Medicine (G.A.M.N., D.-L.N.), Department of Medicine, Mount Sinai Hospital and Toronto General Hospital, University Health Network, University of Toronto, Ontario; Department of Human Genetics (J.P.R., P.A.D., G.A.R., Z.G.-O.), Montreal Neurological Institute and Hospital (J.P.R., P.A.D., G.A.R., Z.G.-O.), and Department of Neurology and Neurosurgery (P.A.D., G.A.R., Z.G.-O.), McGill University, Quebec; Tanz Centre for Research in Neurodegenerative Diseases (M.Z., E.A.R., L.V.K.), University of Toronto, Ontario, Canada; Shanghai First Rehabilitation Hospital (M.Z.), School of Medicine, Clinical Center for Brain and Spinal Cord Research (M.Z.), and Institute for Advanced Study (M.Z.), Tongji University, Shanghai, China; Department of Neurology (D. Arkadir, M.G.), Hadassah Medical Center, Hebrew University, Jerusalem, Israel; Ellen and Martin Prosserman Centre for Neuromuscular Diseases (C.B.), Division of Neurology, Department of Medicine, Toronto General Hospital, University Health Network, University of Toronto; London Health Sciences Centre (C.L.S.), London, Ontario, Canada; Gaucher Unit (A.Z.), Shaare Zedek Medical Center, Hadassah Medical School, Hebrew University, Jerusalem, Israel; Division of Neurology (L.Z.), Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto; and Edmond J. Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Clinic (L.V.K.), Division of Neurology, Department of Medicine, Toronto Western Hospital, University Health Network, University of Toronto, Ontario, Canada
| | - Dayna-Lynn Nevay
- From the Krembil Research Institute (L.M.O., L.V.K.), Toronto Western Hospital, University Health Network, Ontario; Djavad Mowafaghian Centre for Brain Health (T.R.), Division of Neurology, Department of Medicine, University of British Columbia, Vancouver; Mark Feedman and Judy Jacobs Program for Gaucher Disease (G.A.M.N., D. Amato, L.V.K.), Mount Sinai Hospital; Fred A. Litwin Family Centre for Genetic Medicine (G.A.M.N., D.-L.N.), Department of Medicine, Mount Sinai Hospital and Toronto General Hospital, University Health Network, University of Toronto, Ontario; Department of Human Genetics (J.P.R., P.A.D., G.A.R., Z.G.-O.), Montreal Neurological Institute and Hospital (J.P.R., P.A.D., G.A.R., Z.G.-O.), and Department of Neurology and Neurosurgery (P.A.D., G.A.R., Z.G.-O.), McGill University, Quebec; Tanz Centre for Research in Neurodegenerative Diseases (M.Z., E.A.R., L.V.K.), University of Toronto, Ontario, Canada; Shanghai First Rehabilitation Hospital (M.Z.), School of Medicine, Clinical Center for Brain and Spinal Cord Research (M.Z.), and Institute for Advanced Study (M.Z.), Tongji University, Shanghai, China; Department of Neurology (D. Arkadir, M.G.), Hadassah Medical Center, Hebrew University, Jerusalem, Israel; Ellen and Martin Prosserman Centre for Neuromuscular Diseases (C.B.), Division of Neurology, Department of Medicine, Toronto General Hospital, University Health Network, University of Toronto; London Health Sciences Centre (C.L.S.), London, Ontario, Canada; Gaucher Unit (A.Z.), Shaare Zedek Medical Center, Hadassah Medical School, Hebrew University, Jerusalem, Israel; Division of Neurology (L.Z.), Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto; and Edmond J. Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Clinic (L.V.K.), Division of Neurology, Department of Medicine, Toronto Western Hospital, University Health Network, University of Toronto, Ontario, Canada
| | - David Arkadir
- From the Krembil Research Institute (L.M.O., L.V.K.), Toronto Western Hospital, University Health Network, Ontario; Djavad Mowafaghian Centre for Brain Health (T.R.), Division of Neurology, Department of Medicine, University of British Columbia, Vancouver; Mark Feedman and Judy Jacobs Program for Gaucher Disease (G.A.M.N., D. Amato, L.V.K.), Mount Sinai Hospital; Fred A. Litwin Family Centre for Genetic Medicine (G.A.M.N., D.-L.N.), Department of Medicine, Mount Sinai Hospital and Toronto General Hospital, University Health Network, University of Toronto, Ontario; Department of Human Genetics (J.P.R., P.A.D., G.A.R., Z.G.-O.), Montreal Neurological Institute and Hospital (J.P.R., P.A.D., G.A.R., Z.G.-O.), and Department of Neurology and Neurosurgery (P.A.D., G.A.R., Z.G.-O.), McGill University, Quebec; Tanz Centre for Research in Neurodegenerative Diseases (M.Z., E.A.R., L.V.K.), University of Toronto, Ontario, Canada; Shanghai First Rehabilitation Hospital (M.Z.), School of Medicine, Clinical Center for Brain and Spinal Cord Research (M.Z.), and Institute for Advanced Study (M.Z.), Tongji University, Shanghai, China; Department of Neurology (D. Arkadir, M.G.), Hadassah Medical Center, Hebrew University, Jerusalem, Israel; Ellen and Martin Prosserman Centre for Neuromuscular Diseases (C.B.), Division of Neurology, Department of Medicine, Toronto General Hospital, University Health Network, University of Toronto; London Health Sciences Centre (C.L.S.), London, Ontario, Canada; Gaucher Unit (A.Z.), Shaare Zedek Medical Center, Hadassah Medical School, Hebrew University, Jerusalem, Israel; Division of Neurology (L.Z.), Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto; and Edmond J. Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Clinic (L.V.K.), Division of Neurology, Department of Medicine, Toronto Western Hospital, University Health Network, University of Toronto, Ontario, Canada
| | - Marc Gotkine
- From the Krembil Research Institute (L.M.O., L.V.K.), Toronto Western Hospital, University Health Network, Ontario; Djavad Mowafaghian Centre for Brain Health (T.R.), Division of Neurology, Department of Medicine, University of British Columbia, Vancouver; Mark Feedman and Judy Jacobs Program for Gaucher Disease (G.A.M.N., D. Amato, L.V.K.), Mount Sinai Hospital; Fred A. Litwin Family Centre for Genetic Medicine (G.A.M.N., D.-L.N.), Department of Medicine, Mount Sinai Hospital and Toronto General Hospital, University Health Network, University of Toronto, Ontario; Department of Human Genetics (J.P.R., P.A.D., G.A.R., Z.G.-O.), Montreal Neurological Institute and Hospital (J.P.R., P.A.D., G.A.R., Z.G.-O.), and Department of Neurology and Neurosurgery (P.A.D., G.A.R., Z.G.-O.), McGill University, Quebec; Tanz Centre for Research in Neurodegenerative Diseases (M.Z., E.A.R., L.V.K.), University of Toronto, Ontario, Canada; Shanghai First Rehabilitation Hospital (M.Z.), School of Medicine, Clinical Center for Brain and Spinal Cord Research (M.Z.), and Institute for Advanced Study (M.Z.), Tongji University, Shanghai, China; Department of Neurology (D. Arkadir, M.G.), Hadassah Medical Center, Hebrew University, Jerusalem, Israel; Ellen and Martin Prosserman Centre for Neuromuscular Diseases (C.B.), Division of Neurology, Department of Medicine, Toronto General Hospital, University Health Network, University of Toronto; London Health Sciences Centre (C.L.S.), London, Ontario, Canada; Gaucher Unit (A.Z.), Shaare Zedek Medical Center, Hadassah Medical School, Hebrew University, Jerusalem, Israel; Division of Neurology (L.Z.), Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto; and Edmond J. Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Clinic (L.V.K.), Division of Neurology, Department of Medicine, Toronto Western Hospital, University Health Network, University of Toronto, Ontario, Canada
| | - Carolina Barnett
- From the Krembil Research Institute (L.M.O., L.V.K.), Toronto Western Hospital, University Health Network, Ontario; Djavad Mowafaghian Centre for Brain Health (T.R.), Division of Neurology, Department of Medicine, University of British Columbia, Vancouver; Mark Feedman and Judy Jacobs Program for Gaucher Disease (G.A.M.N., D. Amato, L.V.K.), Mount Sinai Hospital; Fred A. Litwin Family Centre for Genetic Medicine (G.A.M.N., D.-L.N.), Department of Medicine, Mount Sinai Hospital and Toronto General Hospital, University Health Network, University of Toronto, Ontario; Department of Human Genetics (J.P.R., P.A.D., G.A.R., Z.G.-O.), Montreal Neurological Institute and Hospital (J.P.R., P.A.D., G.A.R., Z.G.-O.), and Department of Neurology and Neurosurgery (P.A.D., G.A.R., Z.G.-O.), McGill University, Quebec; Tanz Centre for Research in Neurodegenerative Diseases (M.Z., E.A.R., L.V.K.), University of Toronto, Ontario, Canada; Shanghai First Rehabilitation Hospital (M.Z.), School of Medicine, Clinical Center for Brain and Spinal Cord Research (M.Z.), and Institute for Advanced Study (M.Z.), Tongji University, Shanghai, China; Department of Neurology (D. Arkadir, M.G.), Hadassah Medical Center, Hebrew University, Jerusalem, Israel; Ellen and Martin Prosserman Centre for Neuromuscular Diseases (C.B.), Division of Neurology, Department of Medicine, Toronto General Hospital, University Health Network, University of Toronto; London Health Sciences Centre (C.L.S.), London, Ontario, Canada; Gaucher Unit (A.Z.), Shaare Zedek Medical Center, Hadassah Medical School, Hebrew University, Jerusalem, Israel; Division of Neurology (L.Z.), Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto; and Edmond J. Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Clinic (L.V.K.), Division of Neurology, Department of Medicine, Toronto Western Hospital, University Health Network, University of Toronto, Ontario, Canada
| | - Christen L. Shoesmith
- From the Krembil Research Institute (L.M.O., L.V.K.), Toronto Western Hospital, University Health Network, Ontario; Djavad Mowafaghian Centre for Brain Health (T.R.), Division of Neurology, Department of Medicine, University of British Columbia, Vancouver; Mark Feedman and Judy Jacobs Program for Gaucher Disease (G.A.M.N., D. Amato, L.V.K.), Mount Sinai Hospital; Fred A. Litwin Family Centre for Genetic Medicine (G.A.M.N., D.-L.N.), Department of Medicine, Mount Sinai Hospital and Toronto General Hospital, University Health Network, University of Toronto, Ontario; Department of Human Genetics (J.P.R., P.A.D., G.A.R., Z.G.-O.), Montreal Neurological Institute and Hospital (J.P.R., P.A.D., G.A.R., Z.G.-O.), and Department of Neurology and Neurosurgery (P.A.D., G.A.R., Z.G.-O.), McGill University, Quebec; Tanz Centre for Research in Neurodegenerative Diseases (M.Z., E.A.R., L.V.K.), University of Toronto, Ontario, Canada; Shanghai First Rehabilitation Hospital (M.Z.), School of Medicine, Clinical Center for Brain and Spinal Cord Research (M.Z.), and Institute for Advanced Study (M.Z.), Tongji University, Shanghai, China; Department of Neurology (D. Arkadir, M.G.), Hadassah Medical Center, Hebrew University, Jerusalem, Israel; Ellen and Martin Prosserman Centre for Neuromuscular Diseases (C.B.), Division of Neurology, Department of Medicine, Toronto General Hospital, University Health Network, University of Toronto; London Health Sciences Centre (C.L.S.), London, Ontario, Canada; Gaucher Unit (A.Z.), Shaare Zedek Medical Center, Hadassah Medical School, Hebrew University, Jerusalem, Israel; Division of Neurology (L.Z.), Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto; and Edmond J. Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Clinic (L.V.K.), Division of Neurology, Department of Medicine, Toronto Western Hospital, University Health Network, University of Toronto, Ontario, Canada
| | - Ari Zimran
- From the Krembil Research Institute (L.M.O., L.V.K.), Toronto Western Hospital, University Health Network, Ontario; Djavad Mowafaghian Centre for Brain Health (T.R.), Division of Neurology, Department of Medicine, University of British Columbia, Vancouver; Mark Feedman and Judy Jacobs Program for Gaucher Disease (G.A.M.N., D. Amato, L.V.K.), Mount Sinai Hospital; Fred A. Litwin Family Centre for Genetic Medicine (G.A.M.N., D.-L.N.), Department of Medicine, Mount Sinai Hospital and Toronto General Hospital, University Health Network, University of Toronto, Ontario; Department of Human Genetics (J.P.R., P.A.D., G.A.R., Z.G.-O.), Montreal Neurological Institute and Hospital (J.P.R., P.A.D., G.A.R., Z.G.-O.), and Department of Neurology and Neurosurgery (P.A.D., G.A.R., Z.G.-O.), McGill University, Quebec; Tanz Centre for Research in Neurodegenerative Diseases (M.Z., E.A.R., L.V.K.), University of Toronto, Ontario, Canada; Shanghai First Rehabilitation Hospital (M.Z.), School of Medicine, Clinical Center for Brain and Spinal Cord Research (M.Z.), and Institute for Advanced Study (M.Z.), Tongji University, Shanghai, China; Department of Neurology (D. Arkadir, M.G.), Hadassah Medical Center, Hebrew University, Jerusalem, Israel; Ellen and Martin Prosserman Centre for Neuromuscular Diseases (C.B.), Division of Neurology, Department of Medicine, Toronto General Hospital, University Health Network, University of Toronto; London Health Sciences Centre (C.L.S.), London, Ontario, Canada; Gaucher Unit (A.Z.), Shaare Zedek Medical Center, Hadassah Medical School, Hebrew University, Jerusalem, Israel; Division of Neurology (L.Z.), Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto; and Edmond J. Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Clinic (L.V.K.), Division of Neurology, Department of Medicine, Toronto Western Hospital, University Health Network, University of Toronto, Ontario, Canada
| | - Ekaterina A. Rogaeva
- From the Krembil Research Institute (L.M.O., L.V.K.), Toronto Western Hospital, University Health Network, Ontario; Djavad Mowafaghian Centre for Brain Health (T.R.), Division of Neurology, Department of Medicine, University of British Columbia, Vancouver; Mark Feedman and Judy Jacobs Program for Gaucher Disease (G.A.M.N., D. Amato, L.V.K.), Mount Sinai Hospital; Fred A. Litwin Family Centre for Genetic Medicine (G.A.M.N., D.-L.N.), Department of Medicine, Mount Sinai Hospital and Toronto General Hospital, University Health Network, University of Toronto, Ontario; Department of Human Genetics (J.P.R., P.A.D., G.A.R., Z.G.-O.), Montreal Neurological Institute and Hospital (J.P.R., P.A.D., G.A.R., Z.G.-O.), and Department of Neurology and Neurosurgery (P.A.D., G.A.R., Z.G.-O.), McGill University, Quebec; Tanz Centre for Research in Neurodegenerative Diseases (M.Z., E.A.R., L.V.K.), University of Toronto, Ontario, Canada; Shanghai First Rehabilitation Hospital (M.Z.), School of Medicine, Clinical Center for Brain and Spinal Cord Research (M.Z.), and Institute for Advanced Study (M.Z.), Tongji University, Shanghai, China; Department of Neurology (D. Arkadir, M.G.), Hadassah Medical Center, Hebrew University, Jerusalem, Israel; Ellen and Martin Prosserman Centre for Neuromuscular Diseases (C.B.), Division of Neurology, Department of Medicine, Toronto General Hospital, University Health Network, University of Toronto; London Health Sciences Centre (C.L.S.), London, Ontario, Canada; Gaucher Unit (A.Z.), Shaare Zedek Medical Center, Hadassah Medical School, Hebrew University, Jerusalem, Israel; Division of Neurology (L.Z.), Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto; and Edmond J. Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Clinic (L.V.K.), Division of Neurology, Department of Medicine, Toronto Western Hospital, University Health Network, University of Toronto, Ontario, Canada
| | - Lorne Zinman
- From the Krembil Research Institute (L.M.O., L.V.K.), Toronto Western Hospital, University Health Network, Ontario; Djavad Mowafaghian Centre for Brain Health (T.R.), Division of Neurology, Department of Medicine, University of British Columbia, Vancouver; Mark Feedman and Judy Jacobs Program for Gaucher Disease (G.A.M.N., D. Amato, L.V.K.), Mount Sinai Hospital; Fred A. Litwin Family Centre for Genetic Medicine (G.A.M.N., D.-L.N.), Department of Medicine, Mount Sinai Hospital and Toronto General Hospital, University Health Network, University of Toronto, Ontario; Department of Human Genetics (J.P.R., P.A.D., G.A.R., Z.G.-O.), Montreal Neurological Institute and Hospital (J.P.R., P.A.D., G.A.R., Z.G.-O.), and Department of Neurology and Neurosurgery (P.A.D., G.A.R., Z.G.-O.), McGill University, Quebec; Tanz Centre for Research in Neurodegenerative Diseases (M.Z., E.A.R., L.V.K.), University of Toronto, Ontario, Canada; Shanghai First Rehabilitation Hospital (M.Z.), School of Medicine, Clinical Center for Brain and Spinal Cord Research (M.Z.), and Institute for Advanced Study (M.Z.), Tongji University, Shanghai, China; Department of Neurology (D. Arkadir, M.G.), Hadassah Medical Center, Hebrew University, Jerusalem, Israel; Ellen and Martin Prosserman Centre for Neuromuscular Diseases (C.B.), Division of Neurology, Department of Medicine, Toronto General Hospital, University Health Network, University of Toronto; London Health Sciences Centre (C.L.S.), London, Ontario, Canada; Gaucher Unit (A.Z.), Shaare Zedek Medical Center, Hadassah Medical School, Hebrew University, Jerusalem, Israel; Division of Neurology (L.Z.), Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto; and Edmond J. Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Clinic (L.V.K.), Division of Neurology, Department of Medicine, Toronto Western Hospital, University Health Network, University of Toronto, Ontario, Canada
| | - Guy A. Rouleau
- From the Krembil Research Institute (L.M.O., L.V.K.), Toronto Western Hospital, University Health Network, Ontario; Djavad Mowafaghian Centre for Brain Health (T.R.), Division of Neurology, Department of Medicine, University of British Columbia, Vancouver; Mark Feedman and Judy Jacobs Program for Gaucher Disease (G.A.M.N., D. Amato, L.V.K.), Mount Sinai Hospital; Fred A. Litwin Family Centre for Genetic Medicine (G.A.M.N., D.-L.N.), Department of Medicine, Mount Sinai Hospital and Toronto General Hospital, University Health Network, University of Toronto, Ontario; Department of Human Genetics (J.P.R., P.A.D., G.A.R., Z.G.-O.), Montreal Neurological Institute and Hospital (J.P.R., P.A.D., G.A.R., Z.G.-O.), and Department of Neurology and Neurosurgery (P.A.D., G.A.R., Z.G.-O.), McGill University, Quebec; Tanz Centre for Research in Neurodegenerative Diseases (M.Z., E.A.R., L.V.K.), University of Toronto, Ontario, Canada; Shanghai First Rehabilitation Hospital (M.Z.), School of Medicine, Clinical Center for Brain and Spinal Cord Research (M.Z.), and Institute for Advanced Study (M.Z.), Tongji University, Shanghai, China; Department of Neurology (D. Arkadir, M.G.), Hadassah Medical Center, Hebrew University, Jerusalem, Israel; Ellen and Martin Prosserman Centre for Neuromuscular Diseases (C.B.), Division of Neurology, Department of Medicine, Toronto General Hospital, University Health Network, University of Toronto; London Health Sciences Centre (C.L.S.), London, Ontario, Canada; Gaucher Unit (A.Z.), Shaare Zedek Medical Center, Hadassah Medical School, Hebrew University, Jerusalem, Israel; Division of Neurology (L.Z.), Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto; and Edmond J. Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Clinic (L.V.K.), Division of Neurology, Department of Medicine, Toronto Western Hospital, University Health Network, University of Toronto, Ontario, Canada
| | - Ziv Gan-Or
- From the Krembil Research Institute (L.M.O., L.V.K.), Toronto Western Hospital, University Health Network, Ontario; Djavad Mowafaghian Centre for Brain Health (T.R.), Division of Neurology, Department of Medicine, University of British Columbia, Vancouver; Mark Feedman and Judy Jacobs Program for Gaucher Disease (G.A.M.N., D. Amato, L.V.K.), Mount Sinai Hospital; Fred A. Litwin Family Centre for Genetic Medicine (G.A.M.N., D.-L.N.), Department of Medicine, Mount Sinai Hospital and Toronto General Hospital, University Health Network, University of Toronto, Ontario; Department of Human Genetics (J.P.R., P.A.D., G.A.R., Z.G.-O.), Montreal Neurological Institute and Hospital (J.P.R., P.A.D., G.A.R., Z.G.-O.), and Department of Neurology and Neurosurgery (P.A.D., G.A.R., Z.G.-O.), McGill University, Quebec; Tanz Centre for Research in Neurodegenerative Diseases (M.Z., E.A.R., L.V.K.), University of Toronto, Ontario, Canada; Shanghai First Rehabilitation Hospital (M.Z.), School of Medicine, Clinical Center for Brain and Spinal Cord Research (M.Z.), and Institute for Advanced Study (M.Z.), Tongji University, Shanghai, China; Department of Neurology (D. Arkadir, M.G.), Hadassah Medical Center, Hebrew University, Jerusalem, Israel; Ellen and Martin Prosserman Centre for Neuromuscular Diseases (C.B.), Division of Neurology, Department of Medicine, Toronto General Hospital, University Health Network, University of Toronto; London Health Sciences Centre (C.L.S.), London, Ontario, Canada; Gaucher Unit (A.Z.), Shaare Zedek Medical Center, Hadassah Medical School, Hebrew University, Jerusalem, Israel; Division of Neurology (L.Z.), Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto; and Edmond J. Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Clinic (L.V.K.), Division of Neurology, Department of Medicine, Toronto Western Hospital, University Health Network, University of Toronto, Ontario, Canada
| | - Dominick Amato
- From the Krembil Research Institute (L.M.O., L.V.K.), Toronto Western Hospital, University Health Network, Ontario; Djavad Mowafaghian Centre for Brain Health (T.R.), Division of Neurology, Department of Medicine, University of British Columbia, Vancouver; Mark Feedman and Judy Jacobs Program for Gaucher Disease (G.A.M.N., D. Amato, L.V.K.), Mount Sinai Hospital; Fred A. Litwin Family Centre for Genetic Medicine (G.A.M.N., D.-L.N.), Department of Medicine, Mount Sinai Hospital and Toronto General Hospital, University Health Network, University of Toronto, Ontario; Department of Human Genetics (J.P.R., P.A.D., G.A.R., Z.G.-O.), Montreal Neurological Institute and Hospital (J.P.R., P.A.D., G.A.R., Z.G.-O.), and Department of Neurology and Neurosurgery (P.A.D., G.A.R., Z.G.-O.), McGill University, Quebec; Tanz Centre for Research in Neurodegenerative Diseases (M.Z., E.A.R., L.V.K.), University of Toronto, Ontario, Canada; Shanghai First Rehabilitation Hospital (M.Z.), School of Medicine, Clinical Center for Brain and Spinal Cord Research (M.Z.), and Institute for Advanced Study (M.Z.), Tongji University, Shanghai, China; Department of Neurology (D. Arkadir, M.G.), Hadassah Medical Center, Hebrew University, Jerusalem, Israel; Ellen and Martin Prosserman Centre for Neuromuscular Diseases (C.B.), Division of Neurology, Department of Medicine, Toronto General Hospital, University Health Network, University of Toronto; London Health Sciences Centre (C.L.S.), London, Ontario, Canada; Gaucher Unit (A.Z.), Shaare Zedek Medical Center, Hadassah Medical School, Hebrew University, Jerusalem, Israel; Division of Neurology (L.Z.), Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto; and Edmond J. Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Clinic (L.V.K.), Division of Neurology, Department of Medicine, Toronto Western Hospital, University Health Network, University of Toronto, Ontario, Canada
| | - Lorraine V. Kalia
- From the Krembil Research Institute (L.M.O., L.V.K.), Toronto Western Hospital, University Health Network, Ontario; Djavad Mowafaghian Centre for Brain Health (T.R.), Division of Neurology, Department of Medicine, University of British Columbia, Vancouver; Mark Feedman and Judy Jacobs Program for Gaucher Disease (G.A.M.N., D. Amato, L.V.K.), Mount Sinai Hospital; Fred A. Litwin Family Centre for Genetic Medicine (G.A.M.N., D.-L.N.), Department of Medicine, Mount Sinai Hospital and Toronto General Hospital, University Health Network, University of Toronto, Ontario; Department of Human Genetics (J.P.R., P.A.D., G.A.R., Z.G.-O.), Montreal Neurological Institute and Hospital (J.P.R., P.A.D., G.A.R., Z.G.-O.), and Department of Neurology and Neurosurgery (P.A.D., G.A.R., Z.G.-O.), McGill University, Quebec; Tanz Centre for Research in Neurodegenerative Diseases (M.Z., E.A.R., L.V.K.), University of Toronto, Ontario, Canada; Shanghai First Rehabilitation Hospital (M.Z.), School of Medicine, Clinical Center for Brain and Spinal Cord Research (M.Z.), and Institute for Advanced Study (M.Z.), Tongji University, Shanghai, China; Department of Neurology (D. Arkadir, M.G.), Hadassah Medical Center, Hebrew University, Jerusalem, Israel; Ellen and Martin Prosserman Centre for Neuromuscular Diseases (C.B.), Division of Neurology, Department of Medicine, Toronto General Hospital, University Health Network, University of Toronto; London Health Sciences Centre (C.L.S.), London, Ontario, Canada; Gaucher Unit (A.Z.), Shaare Zedek Medical Center, Hadassah Medical School, Hebrew University, Jerusalem, Israel; Division of Neurology (L.Z.), Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto; and Edmond J. Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Clinic (L.V.K.), Division of Neurology, Department of Medicine, Toronto Western Hospital, University Health Network, University of Toronto, Ontario, Canada
| |
Collapse
|
15
|
Kurashige T, Kuramochi M, Ohsawa R, Yamashita Y, Shioi G, Morino H, Kamada M, Ayaki T, Ito H, Sotomaru Y, Maruyama H, Kawakami H. Optineurin defects cause TDP43-pathology with autophagic vacuolar formation. Neurobiol Dis 2020; 148:105215. [PMID: 33296728 DOI: 10.1016/j.nbd.2020.105215] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2020] [Revised: 11/24/2020] [Accepted: 12/03/2020] [Indexed: 11/17/2022] Open
Abstract
We previously showed that optineurin (OPTN) mutations lead to the development of amyotrophic lateral sclerosis. The association between OPTN mutations and the pathogenesis of amyotrophic lateral sclerosis remains unclear. To investigate the mechanism underlying its pathogenesis, we generated Optn knockout mice. We evaluated histopathological observations of these mice and compared with those of OPTN- amyotrophic lateral sclerosis cases to investigate the mechanism underlying the pathogenesis of amyotrophic lateral sclerosis caused by OPTN mutations. The Optn (-/-) mice presented neuronal autophagic vacuoles immunopositive for charged multivesicular body protein 2b, one of the hallmarks of granulovacuolar degenerations, in the cytoplasm of spinal cord motor neurons at the age of 8 months and the OPTN- amyotrophic lateral sclerosis case with homozygous Q398X mutation. In addition, Optn (-/-) mice showed TAR-DNA binding protein 43/sequestosome1/p62 -positive cytoplasmic inclusions and the clearance of nuclear TAR-DNA binding protein 43. The axonal degeneration of the sciatic nerves was observed in Optn (-/-) mice. However, we could not observe significant differences in survival time, body weight, and motor functions, at 24 months. Our findings suggest that homozygous OPTN deletion or mutations might result in autophagic dysfunction and TAR-DNA binding protein 43 mislocalization, thereby leading to neurodegeneration of motor neurons. These findings indicate that the Optn (-/-) mice recapitulate both common and specific pathogenesis of amyotrophic lateral sclerosis associated with autophagic abnormalities. Optn (-/-) mice could serve as a mouse model for the development of therapeutic strategies.
Collapse
Affiliation(s)
- Takashi Kurashige
- Department of Neurology, National Hospital Organization Kure Medical Center and Chugoku Cancer Center, 3-1 Aoyama-machi, Kure 737-0023, Japan
| | - Masahito Kuramochi
- Department of Epidemiology, Research Institute for Radiation Biology and Medicine, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8553, Japan
| | - Ryosuke Ohsawa
- Department of Epidemiology, Research Institute for Radiation Biology and Medicine, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8553, Japan
| | - Yui Yamashita
- Animal Resource Development Unit, RIKEN Center for Biosystems Dynamics Research, 2-2-3 Minatojima Minami-machi, Chuou-ku, Kobe 650-0047, Japan; Laboratory for Genetic Engineering, RIKEN Center for Biosystems Dynamics Research, Kobe 650-0047, Japan
| | - Go Shioi
- Laboratory for Genetic Engineering, RIKEN Center for Biosystems Dynamics Research, Kobe 650-0047, Japan
| | - Hiroyuki Morino
- Department of Epidemiology, Research Institute for Radiation Biology and Medicine, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8553, Japan
| | - Masaki Kamada
- Department of Neurological Intractable Disease Research, Kagawa University Faculty of Medicine, Kagawa 761-0793, Japan
| | - Takashi Ayaki
- Department of Neurology, Kyoto University Graduate School of Medicine, 54 Kawaramachi, Shogoin, Sakyo-ku Kyoto 606-8507, Japan
| | - Hidefumi Ito
- Department of Neurology, Wakayama Medical University, 811-1 Kimiidera, Wakayama 641-8509, Japan
| | - Yusuke Sotomaru
- Natural Science Center for Basic Research and Development, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8553, Japan
| | - Hirofumi Maruyama
- Department of Clinical Neuroscience and Therapeutics, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8553, Japan
| | - Hideshi Kawakami
- Department of Epidemiology, Research Institute for Radiation Biology and Medicine, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8553, Japan.
| |
Collapse
|
16
|
Korb MK, Kimonis VE, Mozaffar T. Multisystem proteinopathy: Where myopathy and motor neuron disease converge. Muscle Nerve 2020; 63:442-454. [PMID: 33145792 DOI: 10.1002/mus.27097] [Citation(s) in RCA: 30] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2020] [Revised: 10/08/2020] [Accepted: 10/18/2020] [Indexed: 12/12/2022]
Abstract
Multisystem proteinopathy (MSP) is a pleiotropic group of inherited disorders that cause neurodegeneration, myopathy, and bone disease, and share common pathophysiology. Originally referred to as inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia (IBMPFD), attributed to mutations in the gene encoding valosin-containing protein (VCP), it has more recently been discovered that there are several other genes responsible for similar clinical and pathological phenotypes with muscle, brain, nerve, and bone involvement, in various combinations. These include heterogeneous nuclear ribonucleoprotein A2B1 and A1 (hnRNPA2B1, hnRNPA1), sequestosome 1 (SQSTM1), matrin 3 (MATR3), T-cell restricted intracellular antigen 1 (TIA1), and optineurin (OPTN), all of which share disruption of RNA stress granule function and autophagic degradation. This review will discuss each of the genes implicated in MSP, exploring the molecular pathogenesis, clinical features, current standards of care, and future directions for this diverse yet mechanistically linked spectrum of disorders.
Collapse
Affiliation(s)
- Manisha K Korb
- Departments of Neurology, University of California Irvine, Orange, California, USA
| | - Virginia E Kimonis
- Departments of Pediatrics, University of California Irvine, Orange, California, USA
| | - Tahseen Mozaffar
- Departments of Neurology, University of California Irvine, Orange, California, USA.,Departments of Orthopedic Surgery, University of California Irvine, Orange, California, USA.,Departments of Pathology & Laboratory Medicine, University of California Irvine, Orange, California, USA
| |
Collapse
|
17
|
Guo Q, Wang J, Weng Q. The diverse role of optineurin in pathogenesis of disease. Biochem Pharmacol 2020; 180:114157. [PMID: 32687832 DOI: 10.1016/j.bcp.2020.114157] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2020] [Revised: 07/11/2020] [Accepted: 07/14/2020] [Indexed: 02/07/2023]
Abstract
Optineurin is a widely expressed protein that possesses multiple functions. Growing evidence suggests that mutation or dysregulation of optineurin can cause several neurodegenerative diseases, including amyotrophic lateral sclerosis, primary open-angle glaucoma, and Huntington's disease, as well as inflammatory digestive disorders such as Crohn's disease. Optineurin engages in vesicular trafficking, receptor regulation, immune reactions, autophagy, and distinct signaling pathways including nuclear factor kappa beta, by which optineurin contributes to cellular death and related diseases, indicating its potential as a therapeutic target. In this review, we discuss the major functions and signaling pathways of optineurin. Furthermore, we illustrate the influence of optineurin mutation or dysregulation to region-specific pathogenesis as well as potential applications of optineurin in therapeutic strategies.
Collapse
Affiliation(s)
- Qingyi Guo
- Center for Drug Safety Evaluation and Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China
| | - Jincheng Wang
- Center for Drug Safety Evaluation and Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
| | - Qinjie Weng
- Center for Drug Safety Evaluation and Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
| |
Collapse
|
18
|
Stevens CH, Guthrie NJ, van Roijen M, Halliday GM, Ooi L. Increased Tau Phosphorylation in Motor Neurons From Clinically Pure Sporadic Amyotrophic Lateral Sclerosis Patients. J Neuropathol Exp Neurol 2020; 78:605-614. [PMID: 31131395 DOI: 10.1093/jnen/nlz041] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
Amyotrophic lateral sclerosis (ALS) is characterized by the progressive degeneration of motor neurons. There is a pathological and genetic link between ALS and frontotemporal lobar degeneration (FTLD). Although FTLD is characterized by abnormal phosphorylated tau deposition, it is unknown whether tau is phosphorylated in ALS motor neurons. Therefore, this study assessed tau epitopes that are commonly phosphorylated in FTLD, including serine 396 (pS396), 214 (pS214), and 404 (pS404) in motor neurons from clinically pure sporadic ALS cases compared with controls. In ALS lower motor neurons, tau pS396 was observed in the nucleus or the nucleus and cytoplasm. In ALS upper motor neurons, tau pS396 was observed in the nucleus, cytoplasm, or both the nucleus and cytoplasm. Tau pS214 and pS404 was observed only in the cytoplasm of upper and lower motor neurons in ALS. The number of motor neurons (per mm2) positive for tau pS396 and pS214, but not pS404, was significantly increased in ALS. Furthermore, there was a significant loss of phosphorylated tau-negative motor neurons in ALS compared with controls. Together, our data identified a complex relationship between motor neurons positive for tau phosphorylated at specific residues and disease duration, suggesting that tau phosphorylation plays a role in ALS.
Collapse
Affiliation(s)
- Claire H Stevens
- School of Chemistry and Molecular Bioscience, University of Wollongong.,Illawarra Health and Medical Research Institute, Wollongong, New South Wales, Australia
| | - Natalie J Guthrie
- School of Chemistry and Molecular Bioscience, University of Wollongong.,Illawarra Health and Medical Research Institute, Wollongong, New South Wales, Australia
| | | | - Glenda M Halliday
- Brain and Mind Centre, Sydney Medical School, The University of Sydney, Camperdown, New South Wales, Australia
| | - Lezanne Ooi
- School of Chemistry and Molecular Bioscience, University of Wollongong.,Illawarra Health and Medical Research Institute, Wollongong, New South Wales, Australia
| |
Collapse
|
19
|
A novel OPTN variant causing PSP-CBS-like phenotype in familial amyotrophic lateral sclerosis. Parkinsonism Relat Disord 2019; 69:147-149. [PMID: 31759189 DOI: 10.1016/j.parkreldis.2019.11.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/13/2019] [Revised: 10/21/2019] [Accepted: 11/02/2019] [Indexed: 11/22/2022]
|
20
|
Roczniak-Ferguson A, Ferguson SM. Pleiotropic requirements for human TDP-43 in the regulation of cell and organelle homeostasis. Life Sci Alliance 2019; 2:2/5/e201900358. [PMID: 31527135 PMCID: PMC6749094 DOI: 10.26508/lsa.201900358] [Citation(s) in RCA: 31] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2019] [Revised: 08/26/2019] [Accepted: 09/02/2019] [Indexed: 12/12/2022] Open
Abstract
TDP-43 is an RNA-binding protein that forms cytoplasmic aggregates in multiple neurodegenerative diseases. Although the loss of normal TDP-43 functions likely contributes to disease pathogenesis, the cell biological consequences of human TDP-43 depletion are not well understood. We, therefore, generated human TDP-43 knockout (KO) cells and subjected them to parallel cell biological and transcriptomic analyses. These efforts yielded three important discoveries. First, complete loss of TDP-43 resulted in widespread morphological defects related to multiple organelles, including Golgi, endosomes, lysosomes, mitochondria, and the nuclear envelope. Second, we identified a new role for TDP-43 in controlling mRNA splicing of Nup188 (nuclear pore protein). Third, analysis of multiple amyotrophic lateral sclerosis causing TDP-43 mutations revealed a broad ability to support splicing of TDP-43 target genes. However, as some TDP-43 disease-causing mutants failed to fully support the regulation of specific target transcripts, our results raise the possibility of mutation-specific loss-of-function contributions to disease pathology.
Collapse
Affiliation(s)
- Agnes Roczniak-Ferguson
- Department of Cell Biology, Yale University School of Medicine, New Haven, CT, USA.,Department of Neuroscience, Yale University School of Medicine, New Haven, CT, USA.,Program in Cellular Neuroscience, Neurodegeneration and Repair, Yale University School of Medicine, New Haven, CT, USA
| | - Shawn M Ferguson
- Department of Cell Biology, Yale University School of Medicine, New Haven, CT, USA .,Department of Neuroscience, Yale University School of Medicine, New Haven, CT, USA.,Program in Cellular Neuroscience, Neurodegeneration and Repair, Yale University School of Medicine, New Haven, CT, USA
| |
Collapse
|
21
|
Yamaguchi Y, Ayaki T, Li F, Tsujimura A, Kamada M, Ito H, Maki T, Sawamoto N, Urushitani M, Takahashi R. Phosphorylated NF-κB subunit p65 aggregates in granulovacuolar degeneration and neurites in neurodegenerative diseases with tauopathy. Neurosci Lett 2019; 704:229-235. [DOI: 10.1016/j.neulet.2019.03.036] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2018] [Revised: 03/15/2019] [Accepted: 03/20/2019] [Indexed: 10/27/2022]
|
22
|
Toth RP, Atkin JD. Dysfunction of Optineurin in Amyotrophic Lateral Sclerosis and Glaucoma. Front Immunol 2018; 9:1017. [PMID: 29875767 PMCID: PMC5974248 DOI: 10.3389/fimmu.2018.01017] [Citation(s) in RCA: 63] [Impact Index Per Article: 10.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2018] [Accepted: 04/23/2018] [Indexed: 12/11/2022] Open
Abstract
Neurodegenerative disorders, including amyotrophic lateral sclerosis (ALS), frontotemporal dementia, and glaucoma, affect millions of people worldwide. ALS is caused by the loss of motor neurons in the spinal cord, brainstem, and brain, and genetic mutations are responsible for 10% of all ALS cases. Glaucoma is characterized by the loss of retinal ganglion cells and is the most common cause of irreversible blindness. Interestingly, mutations in OPTN, encoding optineurin, are associated with both ALS and glaucoma. Optineurin is a highly abundant protein involved in a wide range of cellular processes, including the inflammatory response, autophagy, Golgi maintenance, and vesicular transport. In this review, we summarize the role of optineurin in cellular mechanisms implicated in neurodegenerative disorders, including neuroinflammation, autophagy, and vesicular trafficking, focusing in particular on the consequences of expression of mutations associated with ALS and glaucoma. This review, therefore showcases the impact of optineurin dysfunction in ALS and glaucoma.
Collapse
Affiliation(s)
- Reka P Toth
- Motor Neuron Disease Research Centre, Department of Biomedical Sciences, Macquarie University, Sydney, NSW, Australia
| | - Julie D Atkin
- Motor Neuron Disease Research Centre, Department of Biomedical Sciences, Macquarie University, Sydney, NSW, Australia.,Department of Biochemistry, La Trobe Institute for Molecular Science, Melbourne, VIC, Australia
| |
Collapse
|
23
|
Ryan TA, Tumbarello DA. Optineurin: A Coordinator of Membrane-Associated Cargo Trafficking and Autophagy. Front Immunol 2018; 9:1024. [PMID: 29867991 PMCID: PMC5962687 DOI: 10.3389/fimmu.2018.01024] [Citation(s) in RCA: 77] [Impact Index Per Article: 12.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2018] [Accepted: 04/24/2018] [Indexed: 12/13/2022] Open
Abstract
Optineurin is a multifunctional adaptor protein intimately involved in various vesicular trafficking pathways. Through interactions with an array of proteins, such as myosin VI, huntingtin, Rab8, and Tank-binding kinase 1, as well as via its oligomerisation, optineurin has the ability to act as an adaptor, scaffold, or signal regulator to coordinate many cellular processes associated with the trafficking of membrane-delivered cargo. Due to its diverse interactions and its distinct functions, optineurin is an essential component in a number of homeostatic pathways, such as protein trafficking and organelle maintenance. Through the binding of polyubiquitinated cargoes via its ubiquitin-binding domain, optineurin also serves as a selective autophagic receptor for the removal of a wide range of substrates. Alternatively, it can act in an ubiquitin-independent manner to mediate the clearance of protein aggregates. Regarding its disease associations, mutations in the optineurin gene are associated with glaucoma and have more recently been found to correlate with Paget’s disease of bone and amyotrophic lateral sclerosis (ALS). Indeed, ALS-associated mutations in optineurin result in defects in neuronal vesicular localisation, autophagosome–lysosome fusion, and secretory pathway function. More recent molecular and functional analysis has shown that it also plays a role in mitophagy, thus linking it to a number of other neurodegenerative conditions, such as Parkinson’s. Here, we review the role of optineurin in intracellular membrane trafficking, with a focus on autophagy, and describe how upstream signalling cascades are critical to its regulation. Current data and contradicting reports would suggest that optineurin is an important and selective autophagy receptor under specific conditions, whereby interplay, synergy, and functional redundancy with other receptors occurs. We will also discuss how dysfunction in optineurin-mediated pathways may lead to perturbation of critical cellular processes, which can drive the pathologies of number of diseases. Therefore, further understanding of optineurin function, its target specificity, and its mechanism of action will be critical in fully delineating its role in human disease.
Collapse
Affiliation(s)
- Thomas A Ryan
- Biological Sciences, University of Southampton, Southampton, United Kingdom
| | - David A Tumbarello
- Biological Sciences, University of Southampton, Southampton, United Kingdom
| |
Collapse
|